Month: September 2016

Mitochondrial Replacement Techniques, the Mexican Case

César-Palacios-Gonzalez

Earlier this week New Scientist broke the news that the first baby born after Maternal Spindle Transfer (a form of mitochondrial replacement) is already five months old, and even more, he seems to be doing well. Even when John Zhang’s team has achieved a world first, I agree with Dr. Alison Murdoch in that: “The …

Mitochondrial Replacement Techniques, the Mexican Case Read More »

First 3-person IVF baby born via “rogue” experiment at Mexico clinic?

John-Zhang-with-3-person-IVF-baby

Today we got the first report of a baby being born via so-called “3-person IVF”, sometimes called 3-parent IVF, in which the DNA of three people contribute to an offspring. Before discussing this further I have to emphasize that we need proof that this is indeed really a 3-person IVF baby via genetic testing. Until that …

First 3-person IVF baby born via “rogue” experiment at Mexico clinic? Read More »

Interview with Fredrik Lanner who is CRISPR’ing healthy human embryos

ssistant-Professor-Fredrik-Lanner--e1474733944943

In the past year there has been a great deal of attention given to the potential use of CRISPR-Cas9 for gene editing in human embryos. An important recent development, described in a new NPR article by Rob Stein, is the use of CRISPR-Cas9 in healthy human embryos for developmental biology research by assistant professor Fredrik …

Interview with Fredrik Lanner who is CRISPR’ing healthy human embryos Read More »

Cynata approval for 1st ever allo trial of IPSC-derived MSCs for GVHD

Cynata

Cynata Therapeutics Limited has received approval from UK regulators to start a first-of-its-kind allogeneic IPSC-based trial of MSCs for graft versus host disease (GVHD). Cynata also had some big news a couple weeks back with a deal with Fujifilm. The company is aiming to recruit 16 patients to test whether the MSCs (a type of adult …

Cynata approval for 1st ever allo trial of IPSC-derived MSCs for GVHD Read More »

KPBS sheds new light on Jim Gass stem cell case, Stemedica

Cesar-Anescua-Jim-Gass

KPBS reporter David Wagner has an important new piece out today on for-profit investigational stem cell treatments and he focuses to a large extent on a stem cell business in San Diego called Stemedica. If you’ve heard of this company it might be in part because they were involved in the Gordie Howe stem cells for stroke story that got …

KPBS sheds new light on Jim Gass stem cell case, Stemedica Read More »

What happens next with FDA & stem cells: lower your expectations?

FDA-draft-guidance

In the total the FDA has held 3 days of public meetings on stem cells in the last few weeks ranging from science to policy and hearing from many parties including patients and even stem cell clinics so the big question now is, “what happens next?” The FDA has 4 draft guidances pertaining to investigational …

What happens next with FDA & stem cells: lower your expectations? Read More »

Google Stem Cell News Stories: Perspectives

Top-stem-cell-headlines

What does Google think (if Google does indeed think) are top 10 stem cell news stories right now? I took a screen shot below. Here are some thoughts on those stories. First, lung organoids are neat, but they have been grown before by several groups. Why is that the top story? I’d have to ask Google. Better …

Google Stem Cell News Stories: Perspectives Read More »

Nominations open for Stem Cell Person of the Year 2016 Award

Stem-cell-person-of-the-year-award

Nominations are open starting today for the Stem Cell Person of the Year Award for 2016. Please email me your nominations: knoepflerATucdavisDOTedu. This is a unique award as it is given to an individual who has taken risks to help others within the stem cell field and they based their actions on outside-the-box thinking. Another …

Nominations open for Stem Cell Person of the Year 2016 Award Read More »

Early, but encouraging data from Asterias on stem cells for spinal cord injury

Asterias

As I posted recently, Asterias Biotherapeutics has had good early safety results so far in its historic stem cell trial for spinal cord injury and now the company presented some early, encouraging hints at efficacy.  However, a caveat here is that this is not an RCT (randomized controlled trial). Ed Wirth, CMO of Asterias, presented the …

Early, but encouraging data from Asterias on stem cells for spinal cord injury Read More »

Report on day 2 of FDA stem cell meeting: patients, researchers, & more

FDA-stem-cell-meeting-day-2

The FDA’s stem cell meeting wrapped up today on day two with a diverse group of individual speakers. A series of patient testimonials today in favor of clinics was one thing that stood out. You can read my take of day one and the account of Jeanne Loring who was at the meeting. I’ve noted that on …

Report on day 2 of FDA stem cell meeting: patients, researchers, & more Read More »